Recruitment unclearEUCTR 2022-001515-10
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease Deme...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesSchizophrenia
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Bulgaria · France and 4 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 380
- Sponsor
- Karuna Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Bulgaria, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2022-001515-10
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease Deme...
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bulgaria · France · Germany
3 more locations
- Italy
- Slovakia
- Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Karuna Therapeutics.
Want to explore more studies?
Explore studiesRelated studies
“Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women” Estudio doble ciego...
"Estudio comparativo, randomizado y de grupos paralelos con PET en pacientes esquizofrénicos de nuevo diagnóstico en tratamiento con Aripiprazol y Risperidona"